Evidence map›Paper›PMID 33127099›Full record

ReviewTrends in pharmacological sciences2020

Electroceuticals in the Gastrointestinal Tract.

Khalil B Ramadi, Shriya S Srinivasan, Giovanni Traverso

Abstract readReview
In one paragraph

Review in Trends in pharmacological sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Electroceuticals: Unlocking the promise of therapies.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024
    Review
  9. Article
  10. Article
  11. Challenges in IBD Research 2024: Novel Technologies.Inflammatory bowel diseases · 2024
    Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Implications of Neural Plasticity in Retinal Prosthesis.Investigative ophthalmology & visual science · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Khalil B RamadiDepartment of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Shriya S SrinivasanDepartment of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Giovanni TraversoDepartment of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address: cgt20@mit.edu.

Funding

CONTROLLED RELEASE OF MACROMOLECULESR01EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL, TRAVERSO, CARLO GIOVANNI · 2002 to 2021
$6.1M
Controlled Release of MacromoleculesR37EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2008 to 2017
$3.9M
Simultaneous gastric and brain electrical interfacing for development of endoscopic gastric stimulation treatments for gastroparesisF32DK122762 · NIDDK · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI RAMADI, KHALIL · 2020 to 2020
$32k
NIBIB NIH HHS R01 EB000244NIBIB NIH HHS R37 EB000244NIDDK NIH HHS F32 DK122762
6 · The paper itself

Abstract

The field of electroceuticals has attracted considerable attention over the past few decades as a novel therapeutic modality. The gastrointestinal (GI) tract (GIT) holds significant potential as a target for electroceuticals as the intersection of neural, endocrine, and immune systems. We review recent developments in electrical stimulation of various portions of the GIT (including esophagus, stomach, and small and large intestine) and nerves projecting to the GIT and supportive organs. This has been tested with varying degrees of success for several dysmotility, inflammatory, hormonal, and neurologic disorders. We outline a vision for the future of GI electroceuticals, building on advances in mechanistic understanding of GI physiology coupled with novel ingestible technologies. The next wave of electroceutical therapies will be minimally invasive and more targeted than current approaches, making them an indispensable tool in the clinical armamentarium.

Indexed as

Electric StimulationGastrointestinal DiseasesHumansPharmaceutical PreparationsPharmaceutical Preparationselectrical stimulationelectroceuticalsgastrointestinal tract

Identifiers

PMID33127099
PMCPMC8186669

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.